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published economic evaluations of dialysis treatment modalities,
including hemodialysis (HD) and peritoneal dialysis (PD).
METHODS: We conducted a systematic literature review of
original research articles comparing PD and HD (or their
subtypes) in both PubMed and EMBASE for the years 1996 to
2006. Articles were included if they 1) came under the major
subject headings of “renal replacement therapy/economics,” or
“dialysis/economics,” or “renal dialysis/economics,” or “hemo-
dialysis units, hospital/economics,” or “kidney failure, chronic/
economics”, and 2) contained the term “peritoneal dialysis” and
either the term “hemodialysis” or “haemodialysis”. Pre-deﬁned
exclusion criteria were also applied. RESULTS: Twenty-ﬁve
articles were included in the formal literature review. The major-
ity of articles were cost evaluations, rather than full economic
evaluations of both costs and outcomes. The results show that, in
developed nations, HD is generally more expensive than PD to
the payer. Research is more limited in developing and emerging
countries. Due to inexpensive labor and high imported equip-
ment and solution costs, PD is perceived to be more expensive
than HD; however, the costs of dialysis differ by region and
additional research is needed in the developing world. CON-
CLUSION: HD is a more expensive dialysis modality in devel-
oped regions of the world. Research in the developing world is
too limited to draw deﬁnitive conclusions.
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OBJECTIVES: Vesicoureteral reﬂux (VUR) occurs in approxi-
mately 1% of infants and children and is associated with recur-
rent urinary tract infections (UTIs). Guidelines in the treatment
of VUR target reducing the number of UTIs in patients with
VUR. Treatment strategies include antibiotic prophylaxis, which
is the current ﬁrst-line treatment, as well as endoscopic injection
and surgery. The objective of this study is to examine the use of
endoscopic injection with dextranomer/hyaluronic acid (Dx/HA)
as a curative option and as an alternative to antibiotic prophy-
laxis as it is gaining in popularity in the treatment of VUR.
METHODS: The nationally representative PharMetrics Inte-
grated Medical and Pharmaceutical database was used to
conduct this retrospective analysis. Patients <11 years of age who
were continuously eligible with an International Classiﬁcation of
Diseases (ICD)-9-CM for VUR were identiﬁed. Resource utiliza-
tion and outcome measures were evaluated over a 6-month pre-
and 12-month post-index period. As randomization is not pos-
sible in a retrospective database analysis, patients were matched
3:1, antibiotic prophylaxis to Dx/HA, by age, gender, urinary
tract infections (UTIs) prior to index date, and diagnosing
physician specialty. The primary outcome assessed was UTIs.
RESULTS: Of the patients, 114 received a prescription for anti-
biotic prophylaxis and 38 underwent endoscopic injection with
Dx/HA between January 2000 and December 2004. The average
number of UTIs per year was 0.28 in the antibiotics cohort and
0.08 in the Dx/HA cohort, respectively. The incidence rate ratio
(IRR) of 4.826 (P = 0.029) revealed that the average number of
UTIs was 3.83 times greater for patients receiving antibiotic
prophylaxis compared with patients who underwent endoscopic
injection. CONCLUSION: Treatment with endoscopic injection
with Dx/HA resulted in signiﬁcantly fewer UTIs compared with
children receiving antibiotic prophylaxis, supporting a role for
Dx/HA as a ﬁrst-line treatment option for patients with VUR.
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OBJECTIVES: Around 1990 there was a social change in the
former socialist countries of Central and Eastern Europe. The
former dominance of the state has changed and many private
health care providers entered into the Hungarian health care
market. The aim of this study is to analyse how the market share
of private dialysis centres has changed. METHODS: Data were
derived from the nationwide database of the Hungarian National
Health Insurance Fund Administration (OEP), the only health
care ﬁnancing agency in Hungary. We analysed the period
between 1995 and 2005. Dialysis centres were classiﬁed into 3
major groups according to their ownership: private, central gov-
ernment (mainly at universities) and local authorities (mainly at
county level hospitals). All the Hungarian dialysis centres are
included into the study regardless of their ownership. RESULTS:
The market share of different type of providers in 1995 from
health insurance expenditures was the following: private provid-
ers 46.3%, central government 20.6% and local authorities
33.1%, which means that public ownership (20.6 + 33.1 = 53.7)
dominated the dialysis care. The market share of providers sig-
niﬁcantly changed for 2005: private providers 89.8%, central
government 5.3% and local authorities 4.9%. Between 1995–
2005 private providers doubled their market share, while dialysis
centres owned by the central government or local authorities lost
15.3 and 28.2 percent point respectively. CONCLUSION: The
ownership structure of dialysis centres dramatically changed in
Hungary after the social and political changes in the early 1990s.
The previous dominance of the state has disappeared, and most
of the dialysis care is provided by private for-proﬁt dialysis
centres.
PUK19
TREATMENT OUTCOMES AND MEDICAL CARE OF PATIENTS
WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO)
RECEIVING BOTULINUMTOXIN A (BOTOX®)THERAPY
Ehlken B1, Bremer J2, Burgdörfer H3, Domurath B4, Hampel C5,
Kutzenberger J4, Seif C6, Sievert KD7,Wefer B6, Bär K8, Berger K1,
Pannek J9
1MERG—Medical Economics Research Group, Munich, Germany,
2Neurologisches Rehabilitationszentrum Greifswald GmbH,
Greifswald, Germany, 3BG-Unfallkrankenhaus Hamburg, Hamburg,
Germany, 4Werner-Wicker-Klinik, Bad Wildungen-Reinhardshausen,
Germany, 5Johannes-Gutenberg-Universität, Mainz, Germany,
6Klinik für Urologie & Kinderurologie des Universitätsklinikums
Schleswig-Holstein, Kiel, Germany, 7Universitätsklinikum Tübingen,
Tübingen, Germany, 8Pharm-Allergan GmbH, Ettlingen, Germany,
9Schweizer Paraplegiker Vereinigung, Nottwil, Switzerland
OBJECTIVES: To evaluate treatment outcomes, medical care
and resource consumption of patients with neurogenic detrusor
overactivity (NDO) before and after botulinum toxin A (BTA)
therapy in Germany. METHODS: In a multi-center, cross-
sectional, retrospective cohort study, information such as demo-
graphic characteristics, number of BTA therapies, urodynamic
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